CAMBRIDGE, Mass. and EXTON, Pa., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
(“Idera” or the “Company”) today announced that it intends to offer and sell up to $50,000,000 of shares of its common stock in an
underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30-day option to purchase
additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the
shares in the offering are to be sold by Idera. Idera intends to use the net proceeds from this offering, together with existing
cash, cash equivalents and investments, to advance clinical development of certain of its programs. J.P. Morgan and Goldman, Sachs
& Co. are acting as joint bookrunning managers for the offering.
The shares are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and
Exchange Commission (the “SEC”) on May 12, 2014 and declared effective by the SEC on May 22, 2014. A preliminary prospectus
supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration
statement. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the
registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities
being offered may also be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 (telephone: 866-803-9204); or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New
York, NY 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered,
nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other
jurisdiction.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the
treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design
synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR
programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the
production of disease-associated proteins by targeting RNA.
Investor Contact Robert Doody Vice President, Investor Relations & Corporate Communications 617-679-5515 (office) 484-639-7235 (mobile) rdoody@iderapharma.com
